NCT07944105
SPARK UPS/MFS: Study Of BET Inhibition With ZEN003694 To Potentiate Anti-Tumor Responses With Radiotherapy To Kickstart Abscopal Effect In Metastatic Undifferentiated Pleomorphic Sarcoma (UPS) And Myxofibrosarcoma (MFS).
StatusNot Yet Recruiting
PhasePhase 1/2
SponsorM.D. Anderson Cancer Center
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Safety and Adverse Events (AEs)
Timeframe: Through study completion; an average of 1 year
Arms and interventions
Phase 1 Dose Escalation: Treatment with ZEN003694 + RTExperimental
Phase 2 Randomized Expansion Arm A: Treatment with ZEN003694 + RTExperimental
Phase 2 Randomized Expansion Arm B: ObservationExperimental
Phase 2 Randomized Expansion Arm C: Treatment with ZEN003694 AloneExperimental
Drugs: ZEN003694, Radiation Therapy
Sites
1 site in 1 country
- UT MD AndersonHouston, Texas, United States